Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/29/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Michael Riebe

Wrong Dr. Michael Riebe?

Senior Vice President, Pharmaceut...

Phone: (650) ***-****  HQ Phone
Pearl Therapeutics , Inc.
200 Saginaw Drive
Redwood City, California 94063
United States

Company Description: Pearl was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic...   more
Background

Employment History

Board Memberships and Affiliations

  • Steering Committee Member
    Nasal Technology Focus Group
  • Steering Committee Member
    AAPS Inhalation

Education

  • PhD
  • Ph.D. , Analytical Chemistry
    University of Wisconsin - Madison
  • B.A. degree , Chemistry
    Kalamazoo College
17 Total References
Web References
Pearl Therapeutics - Company - Management Team
www.pearltherapeutics.com, 29 Sept 2013 [cached]
Michael Riebe, PhD Senior Vice President, Pharmaceutical Development and Research
...
Michael Riebe, PhD
Senior Vice President, Pharmaceutical Development and Research
Michael Riebe joined Pearl Therapeutics in January 2013 as Vice President, Pharmaceutical Development & Research. Dr. Riebe is responsible for Pearl's pharmaceutical and process development, new product research, project management, and manufacturing functions.
Dr. Riebe has a long track record of experience in developing pharmaceutical products, with deep expertise in the development of inhaled respiratory products. Prior to joining Pearl, he was Vice President of R&D at iCeutica where he was responsible for new product development utilizing that company's proprietary SoluMatrix™ dry nanomilling technology. Prior to iCeutica, Dr. Riebe held various roles including Sr. Scientific Director in Respiratory Product Development, Scientific Strategy Head for Pharmaceutical R&D, and Director of Materials Characterization and Technology Assessment at Merck. Prior to joining Merck, Dr. Riebe was a Director in the Aerosol Science & Technology group at Research Triangle Institute. Dr. Riebe also served as New Product Supply Leader in Respiratory at GSK and Head of Inhalation Product Development in the U.S. for GlaxoWellcome. He has led project teams responsible for inhaled product development for multiple products including Serevent®, Ventolin® HFA, and Seretide®/Advair® HFA. He has also been a consultant for several other companies developing inhaled products and technologies.
Dr. Riebe received his B.A. degree in Chemistry from Kalamazoo College and his Ph.D. in Analytical Chemistry from the University of Wisconsin - Madison. He has served in numerous leadership positions within the American Chemical Society and the American Association for Pharmaceutical Scientists, including Chairman of the AAPS Inhalation and Nasal Technology Focus Group.
Pearl Therapeutics hires ...
www.oindpnews.com [cached]
Pearl Therapeutics hires Michael Riebe | Pearl Therapeutics hires Michael Riebe | . . . Read more
...
Pearl Therapeutics hires Michael Riebe | Pearl Therapeutics hires Michael Riebe | . . . Read more
...
Pearl Therapeutics hires Michael Riebe Jan 172013
Pearl Therapeutics, which is developing several inhaled drugs, has announced that it has hired Michael Riebe as VP, Pharmaceutical Development and Research, effective immediately. Riebe, a past chair and current steering committee member of the AAPS Inhalation and Nasal Technology Focus Group, was most recently VP of Research and Development at iCeutica and previously worked in inhaled drug development at Merck and at Glaxo.
...
Speaking for the management and board of directors, we welcome Mike to the Pearl team."
Management - iCeutica: Evolving Drug Development
iceutica.com, 21 Oct 2012 [cached]
Dr Mike Riebe PhD
Vice President, Research and Development
Dr Riebe is responsible for SoluMatrix™ technology development and all CMC activities including GMP manufacturing of iCeutica's products. He is a former Senior Scientific Director with Merck and Executive Director with GSK, and is recognized internationally as an expert in respiratory product development. Dr Riebe has led a number of cross functional international development teams responsible for the launch of oral and respiratory products in a variety of therapeutic areas.
REDWOOD CITY, CALIF., January 17, 2013 ...
www.nlvpartners.com, 17 Jan 2013 [cached]
REDWOOD CITY, CALIF., January 17, 2013 - Pearl Therapeutics Inc. today announced that Michael Riebe, Ph.D. has joined Pearl Therapeutics as vice president, pharmaceutical development and research, effective immediately.
...
Speaking for the management and board of directors, we welcome Mike to the Pearl team."
Prior to joining Pearl Therapeutics, Dr. Riebe was vice president of research and development at iCeutica where he led development of the Company's pipeline of pain, oncology and respiratory products. Prior to iCeutica, Dr. Riebe held various roles at Merck, most recently senior scientific director in respiratory product development; and at RTI, an independent, nonprofit research and development organization. From 1990 through 2003, Dr. Riebe held several positions in respiratory product development at GlaxoSmithKline and its predecessor, Glaxo Wellcome, where he led project teams responsible for pharmaceutical development of Serevent®, Ventolin® HFA, and Seretide®/Advair® HFA. Dr. Riebe received his B.A. degree in chemistry from Kalamazoo College and his Ph.D. in analytical chemistry from the University of Wisconsin - Madison. He has served in numerous leadership positions within the American Chemical Society and the American Association for Pharmaceutical Scientists, including as chairman of the AAPS Inhalation and Nasal Technology Focus Group.
REDWOOD CITY, CALIF., January 17, 2013 ...
www.pearltherapeutics.com, 17 Jan 2013 [cached]
REDWOOD CITY, CALIF., January 17, 2013 - Pearl Therapeutics Inc. today announced that Michael Riebe, Ph.D. has joined Pearl Therapeutics as vice president, pharmaceutical development and research, effective immediately.
...
Speaking for the management and board of directors, we welcome Mike to the Pearl team."
Prior to joining Pearl Therapeutics, Dr. Riebe was vice president of research and development at iCeutica where he led development of the Company's pipeline of pain, oncology and respiratory products. Prior to iCeutica, Dr. Riebe held various roles at Merck, most recently senior scientific director in respiratory product development; and at RTI, an independent, nonprofit research and development organization. From 1990 through 2003, Dr. Riebe held several positions in respiratory product development at GlaxoSmithKline and its predecessor, Glaxo Wellcome, where he led project teams responsible for pharmaceutical development of Serevent®, Ventolin® HFA, and Seretide®/Advair® HFA. Dr. Riebe received his B.A. degree in chemistry from Kalamazoo College and his Ph.D. in analytical chemistry from the University of Wisconsin - Madison. He has served in numerous leadership positions within the American Chemical Society and the American Association for Pharmaceutical Scientists, including as chairman of the AAPS Inhalation and Nasal Technology Focus Group.
Other People with the name "Riebe":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304